The firm anticipates that point-of-care adoption may attract licensing deals from companies interested in adding the biomarkers to their large laboratory analyzers.
Ortho's assay, which aids in quickly and accurately diagnosing heart attacks, runs on its new Vitros XT 7600 Integrated System, among other Ortho systems.
The company said it got CE marking for use of its Vitros NT-proBNP II immunodiagnostic assay to diagnose and assess heart failure and enable risk stratification.
An increased blood-to-stool ratio in the concentration of bacterial short-chain fatty acids marked higher permeability in the intestinal wall.
The mass spec-based panel using 26 protein biomarkers is being developed to detect heart failure earlier than with existing BNP-only-based tests.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
Researchers reported that elevated high-sensitivity troponin I is strongly associated with increased risk of cardiovascular disease in some populations.
The test can be used to rapidly and accurately identify patients suffering from heart attacks, and to help identify low-risk patients who may be safely discharged, the firm said.
The company is developing point-of-care tests for monitoring kidney function (penKid) and endothelial dysfunction in patients at risk of heart failure.
The test uses the same blood draw of a routine health exam and was designed to be unaffected biotin, a vitamin supplement that may skew some lab test results.